Aug. 17 at 4:26 PM
$PCSA Acquisition and pipeline expansion: In July 2026 Processa completed the acquisition of Vidya, adding BTK inhibitor VT-7208 and advancing multi-indication Phase 2 programs.
Funding for operations: The company raised
$200M gross in a private placement tied to the Vidya acquisition to fund VT-7208 trials into the second half of 2029.
Clinical milestones and timelines: Targeted Phase 2 proof-of-concept data windows include food allergy in H2 2027, chronic spontaneous urticaria (CSU) in H1 2028, and relapsing multiple sclerosis (RMS) in H2 2028.
Program rationalization: Processa returned PCS6422 to Elion and closed the related Phase 2 breast cancer trial following a settlement to focus resources on core assets.
Expenses: R&D spending declined due to a paused NGC-Cap trial, while G&A increased driven by higher professional fees and insurance as operations scale post-acquisition.
